(Alliance News) - Hutchmed (China) Ltd on Wednesday said it has completed enrolment of its phase II/III trial of fruquintinib.
Hutchmed, a Hong Kong-based developer of treatments for cancer and immunological diseases, said it has completed enrollment of its phase II/III trial of fruquintinib in combination with sintilimab as second-line treatment for locally advanced or metastatic renal cell carcinoma in China.
Fruquintinib, also known as Fruzaqla, is developed and marketed in China by Hutchmed. The study is a randomized, open-label, active-controlled study to evaluate the efficacy and safety of fruquintinib in combination with sintilimab versus axitinib or everolimus monotherapy for the second-line treatment of advanced RCC, it explained.
The first patient in China received the first dose in October, 2022, and Hutchmed expects to announce topline results from the study around year-end 2024.
In a separate release on Wednesday, Hutchmed said that fruquintinib and surufatinib will continue to be included in the updated National Reimbursement Drug List in China.
Fruquintinib was first included in the NRDL at the start of 2020, whilst surufatinib was included in January 2022.
Chief Commercial Officer Hong Chen said: "The NRDL has made it possible for our innovative medicines to quickly reach more patients in need across China."
Shares in Hutchmed were up 1.5% to 308.00 pence each in London on Wednesday afternoon.
By Sophie Rose, Alliance News senior reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2023 Alliance News Ltd. All Rights Reserved.
Hutchmed (HCM)